000088316 001__ 88316
000088316 005__ 20200716101431.0
000088316 0247_ $$2doi$$a10.1016/j.clnu.2019.03.010
000088316 0248_ $$2sideral$$a111555
000088316 037__ $$aART-2019-111555
000088316 041__ $$aeng
000088316 100__ $$aPironi, L.
000088316 245__ $$aHome parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An international survey
000088316 260__ $$c2019
000088316 5060_ $$aAccess copy available to the general public$$fUnrestricted
000088316 5203_ $$aBackground & aims: The safety and effectiveness of a home parenteral nutrition (HPN) program depends both on the expertise and the management approach of the HPN center. We aimed to evaluate both the approaches of different international HPN-centers in their provision of HPN and the types of intravenous supplementation (IVS)-admixtures prescribed to patients with chronic intestinal failure (CIF).
Methods: In March 2015, 65 centers from 22 countries enrolled 3239 patients (benign disease 90.1%, malignant disease 9.9%), recording the patient, CIF and HPN characteristics in a structured database. The HPN-provider was categorized as health care system local pharmacy (LP) or independent home care company (HCC). The IVS-admixture was categorized as fluids and electrolytes alone (FE) or parenteral nutrition, either commercially premixed (PA) or customized to the individual patient (CA), alone or plus extra FE (PAFE or CAFE). Doctors of HPN centers were responsible for the IVS prescriptions.
Results: HCC (66%) was the most common HPN provider, with no difference noted between benign-CIF and malignant-CIF. LP was the main modality in 11 countries; HCC prevailed in 4 European countries: Israel, USA, South America and Oceania (p < 0.001). IVS-admixture comprised: FE 10%, PA 17%, PAFE 17%, CA 38%, CAFE 18%. PA and PAFE prevailed in malignant-CIF while CA and CAFE use was greater in benign-CIF (p < 0.001). PA + PAFE prevailed in those countries where LP was the main HPN-provider and CA + CAFE prevailed where the main HPN-provider was HCC (p < 0.001).
Conclusions: This is the first study to demonstrate that HPN provision and the IVS-admixture differ greatly among countries, among HPN centers and between benign-CIF and cancer-CIF. As both HPN provider and IVS-admixture types may play a role in the safety and effectiveness of HPN therapy, criteria to homogenize HPN programs are needed so that patients can have equal access to optimal CIF care.
000088316 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000088316 590__ $$a6.36$$b2019
000088316 592__ $$a1.737$$b2019
000088316 591__ $$aNUTRITION & DIETETICS$$b9 / 89 = 0.101$$c2019$$dQ1$$eT1
000088316 593__ $$aNutrition and Dietetics$$c2019$$dQ1
000088316 593__ $$aCritical Care and Intensive Care Medicine$$c2019$$dQ1
000088316 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000088316 700__ $$aSteiger, E.
000088316 700__ $$aBrandt, C.
000088316 700__ $$aJoly, F.
000088316 700__ $$aWanten, G.
000088316 700__ $$aChambrier, C.
000088316 700__ $$aAimasso, U.
000088316 700__ $$aSasdelli, A.S.
000088316 700__ $$aZeraschi, S.
000088316 700__ $$aKelly, D.
000088316 700__ $$aSzczepanek, K.
000088316 700__ $$aJukes, A.
000088316 700__ $$aDi Caro, S.
000088316 700__ $$aTheilla, M.
000088316 700__ $$aKunecki, M.
000088316 700__ $$aDaniels, J.
000088316 700__ $$aSerlie, M.
000088316 700__ $$aPoullenot, F.
000088316 700__ $$aWu, J.
000088316 700__ $$aCooper, S.C.
000088316 700__ $$aRasmussen, H.H.
000088316 700__ $$aCompher, C.
000088316 700__ $$aSeguy, D.
000088316 700__ $$aCrivelli, A.
000088316 700__ $$aPagano, M.C.
000088316 700__ $$aHughes, S.J.
000088316 700__ $$aGuglielmi, F.W.
000088316 700__ $$aKozjek, N.R.
000088316 700__ $$aSchneider, S.M.
000088316 700__ $$aGillanders, L.
000088316 700__ $$aEllegard, L.
000088316 700__ $$aThibault, R.
000088316 700__ $$aMatras, P.
000088316 700__ $$aZmarzly, A.
000088316 700__ $$aMatysiak, K.
000088316 700__ $$aVan Gossum, A.
000088316 700__ $$aForbes, A.
000088316 700__ $$aWyer, N.
000088316 700__ $$aTaus, M.
000088316 700__ $$aVirgili, N.M.
000088316 700__ $$aO''Callaghan, M.
000088316 700__ $$aChapman, B.
000088316 700__ $$aOsland, E.
000088316 700__ $$aCuerda, C.
000088316 700__ $$aSahin, P.
000088316 700__ $$aJones, L.
000088316 700__ $$aWon Lee, A.D.
000088316 700__ $$aMasconale, L.
000088316 700__ $$aOrlandoni, P.
000088316 700__ $$aIzbéki, F.
000088316 700__ $$aSpaggiari, C.
000088316 700__ $$aBueno, M.
000088316 700__ $$aDoitchinova-Simeonova, M.
000088316 700__ $$aGarde, C.
000088316 700__ $$aSerralde-Zúñiga, A.E.
000088316 700__ $$aOlveira, G.
000088316 700__ $$aKrznaric, Z.
000088316 700__ $$aCzako, L.
000088316 700__ $$aKekstas, G.
000088316 700__ $$0(orcid)0000-0002-7758-3588$$aSanz-Paris, A.$$uUniversidad de Zaragoza
000088316 700__ $$aJáuregui, E.P.
000088316 700__ $$aMurillo, A.Z.
000088316 700__ $$aSchafer, E.
000088316 700__ $$aArends, J.
000088316 700__ $$aSuárez-Llanos, J.P.
000088316 700__ $$aLal, S.
000088316 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000088316 773__ $$g39, 2 (2019), 585–591$$pClin. nutr.$$tClinical Nutrition$$x0261-5614
000088316 8564_ $$s194238$$uhttps://zaguan.unizar.es/record/88316/files/texto_completo.pdf$$yPostprint
000088316 8564_ $$s31958$$uhttps://zaguan.unizar.es/record/88316/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000088316 909CO $$ooai:zaguan.unizar.es:88316$$particulos$$pdriver
000088316 951__ $$a2020-07-16-08:50:32
000088316 980__ $$aARTICLE